Filter posts

Only 12% of Public Biotechs are Profitable

Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, …

Breakthrough Designations Reach 13

One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act …

Results from the BIO Convention 2013 Meeting Analysis of Therapeutic In/Out Licensors

BIO’s results from the BIO 2013 Convention 1×1 meeting analysis conducted to identify trends and intentions …

BIO-Europe Spring Opening Remarks

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring …

A Bright Future for Orphan Disease Indications

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved …

The IPO Road Less Traveled: Form 10

When investors talk about alternate exits for private companies beyond the traditional IPO they are …

Putting a Ring on It: Advice on Successful Drug Development Collaborations

Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, …

Biobuck M&A in Full Gear

The 2012 M&A results are in and trends are mixed. Last year was a down …

A Big Year for Novel Drugs Approvals

What was your top Biopharma highlight for 2012? If it wasn’t the stellar move in …

Harder, Better, Faster, Stronger: Takeaways from Partnering For Cures 2012

The chorus to Kanye West’s 2007 chart-topper Stronger can teach us volumes about speeding drug …